- Home
- Equipment
- north america
- vaccine based
Show results for
Refine by
Vaccine Based Equipment Supplied In North America
11 equipment items found
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-801 is a novel, live virus vaccine based on synthesized horsepox (sHPXV). It is being developed as a potential smallpox preventing vaccine for widespread immunization and national stockpile. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that Tonix ...
by:Vaxxinit based inDallas, TEXAS (USA)
Employs a “multitope” approach to neutralizing the SARS-CoV-2 virus, eliciting a well-balanced B and T-cell response against multiple viral epitopes. Phase 1 and Phase 2 trials of UB-612 have shown UB-612 to be well tolerated, with no significant safety findings to date, and inducing neutralizing titers against Omicron and other variants of concern. UB-612 is now in a Phase 3 ...
Manufactured by:United Biomedical based inNew York, NEW YORK (USA)
Development of vaccines for human health based on a synthetic peptide platform, spanning therapeutic areas such as neurology, allergy, and infectious ...
Manufactured by:POP Biotechnologies, Inc. (POP BIO) based inBuffalo, NEW YORK (USA)
The SNAP (Spontaneous Nanoliposome Antigen Particleization) platform technology is a unique liposome-based system that functions as a potent vaccine adjuvant designed to address functional and practical limitations facing vaccine ...
Manufactured by:Angany Inc. based inSt-Jean, QUEBEC (CANADA)
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology. The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight! The fight against allergy is at the heart of ANGANY’s mission. And it is to overcome the specific challenges of allergy that ANGANY has developed a ...
Manufactured by:Rational Vaccines, Inc. based inWoburn, MASSACHUSETTS (USA)
One of the most celebrated achievements of modern medicine is the eradication of the smallpox virus with the use of a live-attenuated vaccine. We are advancing the applied science of attenuating live viruses to develop an entirely new class of therapeutic and prophylactic herpes treatments, vaccines and diagnostics, through rational design. Our technology is ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
Manufactured by:Bio-Rad Laboratories, Inc. (Antibodies) based inHercules, CALIFORNIA (USA)
The dengue virus (DENV), first isolated in 1943, is assigned to the family Flaviviridae, genus Flavivirus. It has four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and transmission to humans occurs via the Aedes mosquito, mainly Aedes aegypti. Its global reach has mirrored the spread of Aedes aegypti in tropical and subtropical areas (Messina et al. 2014). It is suggested that 390 million ...
Manufactured by:Vitruvian BioMedical, Inc. based inAddison, TEXAS (USA)
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of Alzheimer’s ...
Manufactured by:AIVITA Biomedical, Inc. based in, CALIFORNIA (USA)
AIVITA Biomedical is using its patient-specific vaccine platform to develop a rapidly scalable vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2). AIVITA’s personalized vaccine begins with a basic blood draw, from which the recipient’s own immune cells are extracted and loaded with SARS-CoV-2 antigen. The resulting personalized treatment is designed to create ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to drive sufficient tumor immunogenicity, leading to poor clinical responses.1 The reason for this may be that previous vaccine models used inadequate ...